{{Rsnum
|rsid=883377
|Gene=SLC6A5
|Chromosome=11
|position=20622581
|Orientation=minus
|GMAF=0.2401
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=SLC6A5
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 51.3 | 41.6 | 7.1
| HCB | 78.8 | 19.7 | 1.5
| JPT | 76.1 | 22.1 | 1.8
| YRI | 46.3 | 46.3 | 7.5
| ASW | 42.1 | 49.1 | 8.8
| CHB | 78.8 | 19.7 | 1.5
| CHD | 76.1 | 19.3 | 4.6
| GIH | 73.3 | 24.8 | 2.0
| LWK | 30.9 | 48.2 | 20.9
| MEX | 62.1 | 32.8 | 5.2
| MKK | 33.3 | 46.2 | 20.5
| TSI | 52.9 | 37.3 | 9.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=20859245
|Title=Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol
}}

{{on chip | Affy GenomeWide 6}}